普伐他汀在高危足月子痫前期孕妇中的随机对照试验
这项多中心双盲安慰剂对照试验纳入1120例单胎妊娠、足月子痫前期高危孕妇,从35至37周随机给予普伐他汀20 mg/d或安慰剂直至分娩或41周。主要结局为随机化后因子痫前期分娩,普伐他汀组发生率为14.6%(80/548),安慰剂组为13.6%(74/543),混合效应Cox回归显示无显著效果(HR 1.08,95%CI 0.78-1.49,P=0.65)。
要点
- 足月子痫前期高危孕妇使用普伐他汀20 mg/d未降低因子痫前期分娩的发生率。
- 普伐他汀组与安慰剂组的子痫前期发生率分别为14.6%与13.6%,HR 1.08(95%CI 0.78-1.49,P=0.65)。
- 未发现普伐他汀对次要结局或新生儿不良结局有显著影响。
核心结论
- 在足月子痫前期高危孕妇中,普伐他汀20 mg/d未能降低因子痫前期分娩的发生率。
研究设计与样本
- 多中心、双盲、安慰剂对照试验,随机分配1120例单胎妊娠、足月子痫前期高危孕妇,从35至37周至分娩或41周接受普伐他汀20 mg/d或安慰剂,按意向性分析。
主要发现
- 普伐他汀组子痫前期发生率为14.6%(80/548),安慰剂组为13.6%(74/543)。
- 混合效应Cox回归显示普伐他汀无显著效果(HR 1.08,95%CI 0.78-1.49,P=0.65)。
- 普伐他汀效果与筛查时风险、妊娠史、依从性及阿司匹林治疗之间无交互作用证据。
- 包括妊娠期高血压、死产、胎盘早剥、小于胎龄儿分娩、新生儿死亡或新生儿疾病在内的次要结局组间无显著差异。
- 随机化后1周和3周时血清胎盘生长因子和可溶性fms样酪氨酸激酶-1浓度组间治疗效应无显著差异。
临床怎么用
- 对于足月子痫前期高危孕妇,不推荐使用普伐他汀20 mg/d以预防子痫前期。
局限性
- 试验中29例女性退出知情同意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1120 women with singleton pregnancies at high risk of term preeclampsia to receive pravastatin at a dose of 20 mg/d or placebo from 35 to 37 weeks of gestation until delivery or 41 weeks. The primary outcome was delivery with preeclampsia at any time after randomization. The analysis was performed according to intention to treat. RESULTS: A total of 29 women withdrew consent during the trial. Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Allowing for the effect of risk at the time of screening and participating center, the mixed-effects Cox regression showed no evidence of an effect of pravastatin (hazard ratio for statin/placebo, 1.08 [95% CI, 0.78-1.49]; P=0.65). There was no evidence of interaction between the effect of pravastatin, estimated risk of preeclampsia, pregnancy history, adherence, and aspirin treatment. There was no significant between-group difference in the incidence of any secondary outcomes, including gestational hypertension, stillbirth, abruption, delivery of small for gestational age neonates, neonatal death, or neonatal morbidity. There was no significant between-group difference in the treatment effects on serum placental growth factor and soluble fms-like tyrosine kinase-1 concentrations 1 and 3 weeks after randomization. Adherence was good, with reported intake of ≥80% of the required number of tablets in 89% of participants. There were no significant between-group differences in neonatal adverse outcomes or other adverse events. CONCLUSIONS: Pravastatin in women at high risk of term preeclampsia did not reduce the incidence of delivery with preeclampsia. Registration: URL: https://www.isrctn.com; Unique identifier ISRCTN16123934.
引用
- Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021. PMID: 34162218. doi:10.1161/CIRCULATIONAHA.121.053963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。